All News
TNF Inhibitor Drug-Induced Lupus
A study from the FDA's adverse event reporting system (FAERS or Medwatch) database identified cases of drug induced systemic lupus erythematosus (SLE) in patients receiving tumor necrosis factor-α (TNF-α) inhibitors - a paradoxical reaction to common antiinflammatory biologic agents.
Read Article
Ankle Fusion or Total Replacement?
In a large study of British patients needing surgical treatment for advanced arthritis in the ankle, fusion appeared to be a better option than total ankle replacement.
Read Article
Diagnoses via Immune ‘Fingerprints’
Science and researchers at Stanford Medicine have reported the use of Mal-ID (machine learning for immunological diagnosis) to analyze B and T cell receptors sequences from human blood, showing the ability to predict health status (healthy vs diseased) and discriminate between distinct autoimmune diseases or viral infections, and those who had received an influenza vaccine.
Read Article
Postoperative Weight Loss Improves Joint Replacement Survival
A cohort study of shows that postoperative weight loss with antiobesity medications significantly reduced the risk of 5-year and 10-year revision among patients with obesity undergoing hip or knee replacement.
Read Article
B Cell Depleters (2.21.2025)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
CRP and Hidradenitis Supprativa
A post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II) of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI.
Read Article
Targeting PD-1 in Rheumatoid Arthritis
The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.
Read Article
The Cartel is Coming for Rheumatology
"What Do Blockbuster Drugs & The Black Market All Have in Common?" asked Dr. Madelaine Feldman at RheumNow Live 2025. They thrive, she explained, on market exclusivity "... until they don't." At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr. Feldman of Tulane University described how sinister forces of market manipulation have negatively impacted patient care for years.
Read Article
Combination biologics in PsA: are we there yet?
Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.
Read Article
Valentine RNL 2025 Review (2.14.2025)
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
Read Article
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
